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Abstract
Background: The prognostic factors for the recurrence of lymph node (LN) metastasis after dose-escalated
radiotherapy (RT) in prostate cancer patients have not been well investigated. We report the prognostic factors and
outcomes in patients receiving salvage treatment for LN recurrence after high-dose intensity-modulated RT (IMRT).
Methods: We studied a cohort of 419 patients with localized prostate adenocarcinoma undergoing definitive IMRT
(78 Gy). LN recurrence was diagnosed by size criteria using computed tomography (CT) or magnetic resonance
imaging, or abnormal uptake of 18F-fluorocholine by LNs on positron emission tomography/CT. Overall survival and
LN recurrence-free survival (LNRFS) were calculated, and prognostic factors were evaluated.
Results: With a median follow-up of 60 months, 18 patients (4.3 %) had LN recurrence and a significantly lower
5-year overall survival rate (60 vs. 90 %, p = 0.003). Univariate analysis showed that T3/T4 stage (p = 0.003), Gleason
score >7 (p < 0.001), and estimated risk of pelvic LN involvement of >30 % by the Roach formula (p = 0.029) were
associated with significantly lower LNRFS. On multivariate analysis, high Gleason score (hazard ratio = 5.99, p = 0.007)
was the only independent factor. The 1/2-year overall survivals after LN recurrence were 67/54 %. Patients with
isolated LN recurrence (p = 0.003), prostate-specific antigen (PSA) doubling time >5 months (p = 0.009), interval
between PSA nadir and biochemical failure >12 months (p = 0.035), and PSA <10 ng/ml at LN recurrence (p = 0.003)
had significantly better survival. Patients with isolated LN recurrence had significantly better survival when treated
with combined RT and hormones than when treated with hormones alone (p = 0.011).
Conclusions: Gleason score of >7 may predict LN recurrence in prostate cancer patients treated with definitive
IMRT. Small number of patients limits the extrapolation of this risk with the primary treatment strategy. Combined
RT and hormones may prolong survival in patients with isolated LN recurrence.
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Background
Definitive radiotherapy (RT) is a first-line treatment for
patients with localized prostate cancer (PCa) [1, 2].
Dose-escalated intensity-modulated radiation therapy
(IMRT) has been increasingly used in clinical practice
for PCa [3] and results in satisfactory outcomes and ac-
ceptable toxicity [4–6]. Compared with three-dimensional
conformal radiation therapy, IMRT permits delivery of
higher radiation dose while reducing the risk of gastro-
intestinal toxicity [7–9]. Most dose-escalated radiother-
apies are designed to treat the prostate and seminal
vesicles but not the pelvic lymphatics. Although prophy-
lactic irradiation of lymph nodes has long been recom-
mended for head and neck cancer, rectal cancer, anal
cancer, breast cancer, and certain solid tumors, the thera-
peutic ratio of whole pelvic RT remains unknown for PCa.
Randomized trials have failed to provide solid evidence for
the survival benefit of additional RT to the pelvic lym-
phatics [10–12].
The lymph node is the second most common meta-
static site in prostate cancer [13]. The nomogram to pre-
dict lymph node involvement for prostate cancer was
developed using known prognostic factors, including
pretreatment prostate-specific antigen (PSA), Gleason
score, and clinical stage as the key factors for estimating
the risk of lymph node metastasis [14, 15]. Although the
percentage of lymph node metastasis is low in PCa pa-
tients undergoing radical prostatectomy, lymph node
dissection is known to prolong their survival [16, 17].
However, the prognostic factors that predict the recur-
rence of lymph node metastasis in PCa patients (after
definitive RT directed only to prostate and seminal vesi-
cles) has not been well investigated.
For PCa patients with lymph node recurrence, andro-
gen deprivation therapy (ADT) is the treatment of
choice [1, 2]. The outcomes for PCa patients with lymph
node metastasis vary between studies. Some studies re-
port relatively good outcome in patients with lymph
node recurrence receiving aggressive salvage treatment
[18–20]. In accordance with a trial of dose-escalated RT
at our institution, we have been using definitive IMRT
(78 Gy) for PCa patients since 2003, targeting only the
prostate and involved seminal vesicles. In this study, our
aim was to determine the factors predicting treatment
failure by investigating the characteristics of patients
with lymph node recurrence after definitive RT without
elective pelvic node irradiation and their outcomes with
salvage treatment.
Methods
Patients and diagnostic criteria for lymph node
metastasis
The cohort consisted of 419 Asian patients with non-
metastatic prostate adenocarcinoma treated in our
institute from December 2003 to December 2010. The
study has been approved by the ethical committees related
to the institution in which it was performed, and patients
gave informed consent to the study. All patients under-
went initial treatment with either step-and-shoot IMRT,
tomotherapy, or volumetric modulated arc therapy. In all
patients, the RT dose was 78 Gy in 39 fractions, and the
clinical target volume (CTV) consisted of the prostate and
the involved seminal vesicle(s) but not the pelvic lymph
nodes. The initial treatment with ADT was left to the dis-
cretion of the prescribing physicians. ADT was adminis-
tered neoadjuvantly more than 2 months prior to RT and
continued concurrently with RT. Alternatively, mainten-
ance ADT was administered concurrently with RT and
was continued after RT. Patients typically received
gonadotropin-releasing hormone (GnRH) agonist as
monotherapy. An oral anti-androgen was usually initiated
at the start of GnRH agonist therapy to prevent a rebound
surge of androgen.
Biochemical failure after the primary RT was defined
according to the Phoenix definition (PSA elevation ex-
ceeding PSA nadir by 2 ng/ml). The diagnosis of lymph
node metastasis was based on the following criteria: the
short-axis diameter of the lymph node was elongated
and exceeded 10 mm or was rounded and exceeded
8 mm on computed tomography (CT) or magnetic res-
onance imaging (MRI) or abnormal uptake by lymph
nodes of 18F-fluorocholine on positron emission tomog-
raphy (PET)/CT. PSA doubling time was defined as the
time interval needed for serum PSA levels to increase by
100 %. The PSA nadir–biochemical failure interval was
defined as the interval between the lowest PSA level and
the diagnosis of biochemical failure.
Follow-up and toxicity related to salvage treatment
Follow-up duration, survival time, and event time were
calculated from the start of the initial IMRT for the
comparison between patients with and without lymph
node recurrence and from the start of salvage treatment
only for patients with lymph node recurrence. Kaplan-
Meier analysis was performed to determine overall survival
and lymph node recurrence-free survival rates. Treatment-
related toxicities were determined using Common Toxicity
Criteria v.4.0.
Statistical analysis
Descriptive analysis was performed by calculating ranges,
means, medians, and standard deviations. Continuous var-
iables were compared with a two-sided unpaired t test.
Chi-square and Fisher’s exact tests were used for contin-
gency table analysis. The log-rank test was used to deter-
mine prognostic factors affecting survival. All prognostic
variables found to be significant or borderline significant
in univariate analysis were included in multivariate
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analysis using the Cox proportional hazards regression
model. Significance was assumed if p < 0.05. All statistics
were done with PASW Statistics 18 (IBM Corp., Armonk,
NY, USA).
Results
Differences in characteristics between patients with and
without lymph node recurrence
With a median follow-up of 60 months, 18 of 419 pa-
tients (4.3 %) had lymph node recurrence. Of these 18
patients, 3 patients had initial T1, 4 had T2, 9 had T3,
and 2 had T4 disease. Eleven patients (61.1 %) had a
Gleason score of 8 or higher. The median value of initial
PSA was 18.4 ng/ml (range 4.8–101.5). Sixteen patients
(88.8 %) had high risk or very high risk of PCa according
to the National Comprehensive Cancer Network
(NCCN) classification. Their characteristics are shown
in Table 1.
As shown in Fig. 1, the 5-year overall survival rate was
significantly lower in patients with lymph node recur-
rence (60 vs. 90 %, p = 0.003). Univariate analysis identi-
fied advanced T stage (T3/T4 vs. T1/T2) (p = 0.003),
high Gleason score (>7 vs. ≤7) (p < 0.001), and the esti-
mated risk of pelvic lymph node involvement by the
Roach formula of more than 30 % (p = 0.029) as factors
associated with higher risk of lymph node recurrence.
On multivariate analysis, high Gleason score (hazard
ratio = 5.99, p = 0.007) was the only independent prog-
nostic factor for lymph node recurrence, while ad-
vanced T stage was of borderline significance (hazard
ratio = 2.68, p = 0.074) (Table 2).
Salvage treatment in patients with lymph node
recurrence
Of the 18 patients with lymph node recurrence, 13 pa-
tients had isolated lymph node recurrence, defined as
any recurrence at nodal regions without other distant
metastasis. Eight patients had pelvic lymph node recur-
rence alone (N1); 2 had simultaneous pelvic and para-
aortic lymph node recurrences (M1a); and 3 had neck,
axilla, and anterior mediastinum lymph node recur-
rences (M1a). The median time from primary radiation
therapy to biochemical failure was 36 months (range
15–99). Recurrence in 9 patients was diagnosed by both
18F-fluorocholine PET/CT and MRI, 8 by CT and 1 by
MRI. At the diagnosis of lymph node recurrence, the
median age was 71.5 years, the median PSA level was
20.0 ng/ml (range 2.0–680), and the median PSA nadir-
failure interval was 16.7 months (range 5.9–76.2). All pa-
tients with lymph node recurrence received salvage hor-
mone treatment. Of the 13 patients with isolated lymph
node recurrence, 6 patients underwent additional RT
with a median dose of 55 Gy (range 55–63) to the in-
volved lymph nodes. All 6 patients had a normal PSA
level after salvage RT for a median of 17 months. One
patient with isolated lymph node recurrence underwent
salvage pelvic lymph node dissection, had a second
Table 1 Patient/tumor characteristics and the use of androgen
deprivation therapy (ADT) between patients without (n = 401)
and with (n = 18) lymph node (LN) recurrence
Variable Without LN With LN
Number (%) Number (%)
Age
<70 134 (33.4) 5 (27.7)
≥70 267 (66.6) 13 (72.3)
T stage
1a 5 (1.2) 0 (0)
1b 6 (1.5) 0 (0)
1c 124 (30.9) 3 (16.7)
2a 52 (13.0) 1 (5.6)
2b 40 (10.0) 3 (16.7)
2c 42 (10.5) 0 (0)
3a 72 (18.0) 2 (11.1)
3b 53 (13.2) 7 (38.9)
4 7 (1.7) 2 (11.1)
Gleason score
<7 125 (31.2) 3 (16.7)
7 185 (46.1) 4 (22.2)
8–10 91 (22.7) 11 (61.1)
PSA (ng/ml)
<10 117 (29.2) 4 (22.2)
10–20 119 (29.7) 5 (27.7)
≥20 165 (41.1) 9 (50.0)
Risk group
Low 41 (10.2) 1 (5.6)
Intermediate 121 (30.2) 1 (5.6)
High 180 (44.9) 7 (38.9)
Very high 59 (14.7) 9 (50.0)
Any ADT
No 57 (14.2) 2 (11.1)
Yes 344 (85.8) 16 (88.9)
Neoadjuvant ADT
No 127 (31.7) 4 (22.2)
Yes 274 (68.3) 14 (77.8)
Concurrent ADT
No 103 (25.7) 8 (44.4)
Yes 298 (74.3) 10 (55.6)
Maintenance ADT
No 177 (44.1) 9 (50.0)
Yes 224 (55.9) 9 (50.0)
Wang et al. World Journal of Surgical Oncology  (2015) 13:312 Page 3 of 7
biochemical failure, and received salvage RT resulting in
PSA control. Six patients with isolated lymph node recur-
rence received hormone therapy alone, with 4 of them ex-
periencing disease progression. One of them with initial
pelvic lymph node recurrence had subsequent para-aortic
lymph node recurrence and received additional salvage RT.
Survivals and prognostic factors after salvage treatment
for lymph node recurrence
With a median follow-up of 12 months from the salvage
treatment, 7 patients died, with 6 of them due to pros-
tate cancer. Relapse of lymph node metastasis occurred
after treatment in one patient and subsequently to other
lymph nodes in 11 patients; 5 patients had bone metas-
tasis. The 1- and 2-year overall survival rates after lymph
node recurrence were 67 and 54 %, respectively, with a
median survival of 12.3 months. None of the 18 patients
had more than grade 2 toxicity related to the salvage
treatments. Patients with isolated lymph node recurrence
(p = 0.003), PSA doubling time >5 months (p = 0.009), PSA
nadir-to-biochemical failure interval >12 months (p =
0.035), and PSA <10 ng/ml at the diagnosis of lymph node
recurrence (p = 0.003) had significantly better overall sur-
vival. On multivariate analysis, none of these prognostica-
tors proved to be of significance (Table 3).
Patients with isolated lymph node recurrence treated
with combined RT and hormone therapy
We compared the survival rates between patients with
isolated lymph node recurrence (13 patients) and with
simultaneous lymph node recurrence and distant metas-
tasis (5 patients). The 1- and 2-year survival rates were
83/67 and 0/0 % (p = 0.003), respectively (Fig. 2). For the
13 patients with isolated lymph node recurrence treated
with combined RT and hormone therapy (7 patients) or
hormonal therapy alone (6 patients), the 1- and 2-year
survival rates were 100/100 % (median survival
25.8 months) and 60/0 % (median survival 9.0 months),
respectively (p = 0.011) (Fig. 3).
Discussion
Little is known about the risk factors of lymph node re-
currence in PCa patients after definitive RT as well as
their outcome and prognosis after salvage treatment for
nodal recurrence, especially in the era of dose-escalated
RT. Our current study is the first to focus on the lymph
node recurrence in PCa patients undergoing the 78-Gy
IMRT to the prostate and involved seminal vesicles but
not the pelvic nodes. We identified not only characteris-
tics associated with lymph node recurrence but also the
prognostic factors determining outcome in patients with
nodal recurrence treated by salvage treatment. Moreover,
we showed that RT combined with hormones had great
Fig. 1 Kaplan-Meier analyses of overall survival of 419 prostate
cancer patients without (401 patients) and with (18 patients) lymph
node (LN) recurrence
Table 2 Univariate and multivariate analyses of the prognostic
factors on lymph node recurrence-free survival
Variable 5-year lymph node
recurrence-free rate (%)





T3–T4 93 0.003 2.68 (0.91–7.90) 0.074
T1–T2 98
Gleason score
8–10 98 <0.001 5.99 (1.62–22.14) 0.007
≤7 90
PSA (ng/ml)
≥30 94 0.100 1.26 (0.33–4.82) 0.74
<30 97
RFLN (%)





ADT Androgen deprivation therapy, CI confidence interval, HR hazard ratio,
RFLN Roach formula for the risk of pelvic lymph node metastasis
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therapeutic value in patients with isolated lymph node
recurrence.
Lymph node metastasis, though infrequent, has been
recognized as a negative prognostic factor of PCa, and
its risk of occurrence has been associated certain tumor
characteristics. In our series, the 5-year overall survival
rate was significantly lower in patients with lymph node
recurrence. Previous studies have investigated the prob-
ability of pelvic lymph node involvement using the
established predictive nomogram [14, 15]. Gleason sum
and PSA level were found to predict the risk of lymph
node involvement for post-prostatectomy patients [15].
Our study (which excluded patients receiving elective
pelvic node irradiation) similarly identified Gleason sum
as the only independent factor associated with lymph
node recurrence. In contrast, the usefulness of the Roach
formula as a tool for predicting lymph node metastasis
in contemporary patients is debatable [21, 22]. With
bowel-related quality of life being better in PCa patients
receiving prostate-only RT than whole-pelvis RT [23],
the role of prophylactic lymphatic RT remains unsettled.
For the high-risk PCa patients, questions about the ef-
fects of pelvic nodal irradiation are being addressed by
the ongoing clinical trial (RTOG 0924) [24].
Of note, both N1 and M1a in the current staging sys-
tem are referred to as lymph node metastasis and may
infer a diversity of outcomes. The salvage treatments
Fig. 2 Kaplan-Meier analyses of overall survival of 18 prostate cancer
patients with isolated lymph node recurrence (ILR) (13 patients) and
with simultaneous LN recurrence and distant metastasis (5 patients)
Table 3 Univariate and multivariate analyses of the prognostic
factors on overall survival after lymph node recurrence
2-year survival
rate (%)













Isolated lymph node recurrence
Yes 67 0.003 5.22 (0.50–55.03) 0.169
No 0
PSA doubling time
>5 months 89 0.009 1.869 (0.05–74.19) 0.739
<5 months 17
PSA nadir-free interval
>12 months 80 0.035 1.203 (0.09–15.62) 0.888
<12 months 20
PSA at lymph node recurrence (ng/ml)
>10 19 0.003 510,993 (0–1.22E184) 0.950
<10 100
ADT Androgen deprivation therapy, HR hazard ratio, CI confidence interval
Fig. 3 Kaplan-Meier analyses of overall survival of 13 prostate cancer
patients with exclusive lymph node recurrence treated with combined
radiotherapy and hormone therapy (RT + HT) (seven patients) or
hormonal therapy alone (HT) (six patients)
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and survival rates of PCa patients with lymph node re-
currence were very heterogeneous [25, 26]. Therefore,
prognostic factors predictive of lymph node recurrence
would be expected to help doctors tailor treatment to
achieve the best possible outcome. Pond et al. reported
that median survival was longest in patients with lymph
node-only disease (26.7 months), followed by bone-only
and bone-plus-node disease [25]. Yossepowitch et al.
found that longer PSA doubling time is a favorable prog-
nostic factor in post-prostatectomy patients [26]. More-
over, our univariate analysis identified isolated lymph
node recurrence, PSA nadir-to-biochemical failure inter-
val, and PSA level at the diagnosis of lymph node recur-
rence, in addition to PSA doubling time, as significant
prognostic factors. Modern imaging tools, such as
18F-fluorocholine PET/CT, have increased the detectability
of small and otherwise undetectable lymph node metasta-
ses and thus may increase PCa prevalence at even lower
PSA levels [27–29].
Salvage ADT was given to all our patients as the sug-
gested treatment guideline [2]. Nevertheless, ADT is not a
curative treatment, with most treated patients ultimately
developing castration-resistant disease [30]. Two studies
used an advanced RT technique (stereotactic body radi-
ation therapy) as a salvage modality and achieved safe and
effective local control [18, 31], while other studies per-
formed salvage lymph node dissection and obtained a cer-
tain degree of biochemical response [20, 32]. Additionally,
adjuvant RT had a beneficial impact on survival in pN1
PCa patients with low-volume intermediate-/high-grade
nodal disease and intermediate-volume nodal disease [33].
Metastasis-directed therapy was recommended as a prom-
ising approach with acceptable toxicity for PCa patients
with oligometastasis, mostly with lymph node metastasis
[34]. With isolated LN recurrence representing limited
volume of disease, our series similarly showed that com-
bining RT and hormones (rather than treating with hor-
mones alone) significantly increased survival. The 2-year
survival rate of 100 % and the median survival of
25.8 months were encouraging for this select group of pa-
tients treated with combined modalities including local
RT and systemic hormones.
Unlike surgery, which usually provide nodal dissection
along with radical prostatectomy, RT is more commonly
delivered to prostate and seminal vesicles only. The differ-
ence in primary nodal treatment between the two modal-
ities is reflected in the outcomes of patients with lymph
node metastasis. The 5-year survival rate of 96 % was
shown in a Chinese series of PCa patients with lymph
node metastasis on radical prostatectomy [35], compared
with 60 % in our patients treated by node-sparing RT.
However, the small number of patients (18) and the low
crude rate (4.3 %) of lymph node metastasis from the
whole group in this study limit the extrapolation of the
risk of lymph node metastasis with the primary treatment
strategy including pelvic RT. Besides RT, hormonal ther-
apy has been the effective treatment to improve the sur-
vival outcomes of PCa patients with adverse
characteristics, such as high Gleason score [36].
Our series has limitations. First of all, our data in-
cluded only a small number of patients with lymph node
recurrence, even after a long follow-up period. The small
patient number was likely to be the reason that no sig-
nificant prognostic factor was identified on multivariate
analysis of survival after lymph node recurrence. Ideally,
this limitation might be solved by future multi-center
studies. Secondly, the retrospective nature of the study
and the uncontrolled use of hormone therapy in the pri-
mary treatment might bias estimates of the true preva-
lence of lymph node recurrence. Finally, the heterogeneity
of salvage treatments given after the lymph node recur-
rence unavoidably confounded the prognosis. Further pro-
spective study with longer follow-up time is needed.
Conclusions
In conclusion, our data of PCa patients treated with de-
finitive IMRT and not elective pelvic node irradiation indi-
cated the significant association of high Gleason score
with lymph node recurrence. Isolated lymph node recur-
rence, PSA doubling time of >5 months, PSA nadir-to-
biochemical failure interval of >12 months, and PSA of
<10 ng/ml at the diagnosis of lymph node recurrence were
the factors associated with better overall survival after bio-
chemical failure. For patients with isolated LN recurrence,
the combined use of RT to the involved nodes and hor-
mones resulted in the longer survival.
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